testimonials

This is what users say about our instruments

“Single cell efficacy: 70-93%; Colony efficacy: 58-91% (after optimization) [...] The plating effort (to get single cells) can be lowered compared to limited dilution and FACS single cell deposition by the factor 4-5 [...]”

A. Mayer-Bartschmid Senior Scientist, Bayer AG

Mayer-Bartschmid A., et al. (2017). New single cell deposition technologies with integrated image analysis for cell line development of production cell lines. Poster presentation at ESACT 2017 in Lausanne.

Lovelady C., et al. (2017). Cell printing: a fluidics approach to single cell cloning for manufacturing cell lines. Poster presentation at ESACT 2017 in Lausanne.

 

“The cloning platform presented is suitable for generating clonal cell lines with a probability of ≥99.9%. [...] Overall, the implementation of this novel technology provides significant advantages over traditional methods  with respect to cost, simplicity, timings and flexibility.“

C. Lovelady Senior Scientist, Medimmune

“… By use of a scp, the number of monoclonal cell lines increased six-fold compared to the LD process therefore increasing the number of pools that can be cloned. […] Consequently by implementing both of these technologies the CLC process can be decreased from 9 months to 6 months […]”

A. Mahé Scientist, Novimmune

Mahé A., et al. (2017). Optimization of the cell line construction process for manufacturing purposes using a novel single cell printing technology. Poster presentation at ESACT 2017 in Lausanne.